{"id":390049,"date":"2021-04-06T00:00:00","date_gmt":"2021-04-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2020-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-21T05:24:24","modified_gmt":"2026-04-21T05:24:24","slug":"dlsfim0002-2020-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2020-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Copy\/Paste the key inputs from the product brochure, per guidance from Marketing.<\/p>\n<p>The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-\u03b1) inhibitors (Amgen\u2019s Enbrel, AbbVie\u2019s Humira, Janssen\u2019s Remicade and Simponi \/ Simponi Aria, and UCB\u2019s Cimzia) and two IL-17 inhibitors (Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz). The TNF-\u03b1 inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation, followed by Cosentyx and Taltz in June 2020. The impending entry of additional IL-17 inhibitors (UCB\u2019s bimekizumab and Kyowa Hakko Kirin\u2019s Lumicef) and the first oral targeted therapies\u2014Jak inhibitors\u2014for this indication (Pfizer\u2019s Xeljanz and AbbVie&#8217;s Rinvoq) will also shift market dynamics.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large is the treatable AxSpA population, and how will diagnosis \/ drug-treatment rates change over time?<\/li>\n<li>What are interviewed experts\u2019 insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?<\/li>\n<li>What pipeline products are the most promising, and what sales \/ uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?<\/li>\n<li>What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan<\/p>\n<p>Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research<\/p>\n<p>Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2029, segmented by brands\/generics and epidemiological subpopulations<\/p>\n<p>Emerging therapies: Phase III: 4 drugs; Phase II: 1 drugs<\/p>\n<p><strong>Product description: <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390049","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390049\/revisions"}],"predecessor-version":[{"id":576418,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390049\/revisions\/576418"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}